Wada Hideo, Ichikawa Yuhuko, Ezaki Minoru, Yamamoto Akitaka, Tomida Masaki, Yoshida Masamichi, Fukui Shunsuke, Moritani Isao, Shiraki Katsuya, Shimaoka Motomu, Iba Toshiaki, Suzuki-Inoue Katsue, Shimpo Hideto
Department of General and Laboratory Medicine, Mie Prefectural General Medical Center, Yokkaichi 510-0885, Japan.
Department of Central Laboratory, Mie Prefectural General Medical Center, Yokkaichi 510-0885, Japan.
J Clin Med. 2022 Feb 14;11(4):985. doi: 10.3390/jcm11040985.
Although thrombosis in coronavirus disease 2019 (COVID-19) infection has attracted attention, the mechanism underlying its development remains unclear. The relationship between platelet activation and the severity of COVID-19 infection was compared with that involving other infections. Plasma soluble C-type lectin-like receptor 2 (sCLEC-2) levels were measured in 46 patients with COVID-19 infection and in 127 patients with other infections. The plasma sCLEC-2 levels in patients with COVID-19 infection {median (25th, 75th percentile), 489 (355, 668) ng/L} were significantly higher ( < 0.001) in comparison to patients suffering from other pneumonia {276 (183, 459) ng/L}, and the plasma sCLEC-2 levels of COVID-19 patients with severe {641 (406, 781) ng/L} or critical illness {776 (627, 860) ng/L} were significantly higher ( < 0.01, respectively) in comparison to those with mild illness {375 (278, 484) ng/L}. The ratio of the sCLEC-2 levels to platelets in COVID-19 patients with critical illness of infection was significantly higher ( < 0.01, < 0.001 and < 0.05, respectively) in comparison to COVID-19 patients with mild, moderate or severe illness. Plasma sCLEC-2 levels were significantly higher in patients with COVID-19 infection than in those with other infections, suggesting that platelet activation is triggered and facilitated by COVID-19 infection.
尽管2019冠状病毒病（COVID-19）感染中的血栓形成已引起关注，但其发生发展的潜在机制仍不清楚。将血小板活化与COVID-19感染严重程度之间的关系与其他感染所涉及的关系进行了比较。对46例COVID-19感染患者和127例其他感染患者的血浆可溶性C型凝集素样受体2（sCLEC-2）水平进行了检测。与其他肺炎患者{276（183，459）ng/L}相比，COVID-19感染患者的血浆sCLEC-2水平{中位数（第25、75百分位数），489（355，668）ng/L}显著更高（<0.001），并且与轻症患者{375（278，484）ng/L}相比，重症{641（406，781）ng/L}或危重症{776（627，860）ng/L}的COVID-19患者的血浆sCLEC-2水平显著更高（分别<0.01）。与轻症、中症或重症的COVID-19患者相比，感染危重症的COVID-19患者中sCLEC-2水平与血小板的比值显著更高（分别<0.01、<0.001和<0.05）。COVID-19感染患者的血浆sCLEC-2水平显著高于其他感染患者，这表明COVID-19感染触发并促进了血小板活化。
